Titre : Mitogen-Activated Protein Kinase 3

Mitogen-Activated Protein Kinase 3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Fields
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mitogen-Activated Protein Kinase 3 : Questions médicales les plus fréquentes", "headline": "Mitogen-Activated Protein Kinase 3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mitogen-Activated Protein Kinase 3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-24", "dateModified": "2025-02-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mitogen-Activated Protein Kinase 3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Extracellular Signal-Regulated MAP Kinases", "url": "https://questionsmedicales.fr/mesh/D048049", "about": { "@type": "MedicalCondition", "name": "Extracellular Signal-Regulated MAP Kinases", "code": { "@type": "MedicalCode", "code": "D048049", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.563.567.249" } } }, "about": { "@type": "MedicalCondition", "name": "Mitogen-Activated Protein Kinase 3", "alternateName": "Mitogen-Activated Protein Kinase 3", "code": { "@type": "MedicalCode", "code": "D048052", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Juan Wang", "url": "https://questionsmedicales.fr/author/Juan%20Wang", "affiliation": { "@type": "Organization", "name": "Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea." } }, { "@type": "Person", "name": "Mohammad Shafiq", "url": "https://questionsmedicales.fr/author/Mohammad%20Shafiq", "affiliation": { "@type": "Organization", "name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Kumaravelu Jagavelu", "url": "https://questionsmedicales.fr/author/Kumaravelu%20Jagavelu", "affiliation": { "@type": "Organization", "name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Neeraj Kumar Verma", "url": "https://questionsmedicales.fr/author/Neeraj%20Kumar%20Verma", "affiliation": { "@type": "Organization", "name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Jimut Kanti Ghosh", "url": "https://questionsmedicales.fr/author/Jimut%20Kanti%20Ghosh", "affiliation": { "@type": "Organization", "name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Humphrey visual field made easy for residents.", "datePublished": "2024-09-27", "url": "https://questionsmedicales.fr/article/39331457", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4103/IJO.IJO_2519_23" } }, { "@type": "ScholarlyArticle", "name": "Detection of post-stroke visual field loss by quantification of the retrogeniculate visual pathway.", "datePublished": "2022-05-27", "url": "https://questionsmedicales.fr/article/35640329", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jns.2022.120297" } }, { "@type": "ScholarlyArticle", "name": "Foveal avascular zone vessel density is associated with visual field progression in early-stage glaucoma eyes with central visual field damage.", "datePublished": "2023-10-25", "url": "https://questionsmedicales.fr/article/37880406", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-45541-1" } }, { "@type": "ScholarlyArticle", "name": "Visual feedback in the lower visual field affects postural control during static standing.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35843008", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.gaitpost.2022.07.004" } }, { "@type": "ScholarlyArticle", "name": "Five-Year Visual Field Outcomes of the HORIZON Trial.", "datePublished": "2023-02-21", "url": "https://questionsmedicales.fr/article/36813144", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2023.02.008" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Protein-Serine-Threonine Kinases", "item": "https://questionsmedicales.fr/mesh/D017346" }, { "@type": "ListItem", "position": 6, "name": "Mitogen-Activated Protein Kinases", "item": "https://questionsmedicales.fr/mesh/D020928" }, { "@type": "ListItem", "position": 7, "name": "Extracellular Signal-Regulated MAP Kinases", "item": "https://questionsmedicales.fr/mesh/D048049" }, { "@type": "ListItem", "position": 8, "name": "Mitogen-Activated Protein Kinase 3", "item": "https://questionsmedicales.fr/mesh/D048052" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mitogen-Activated Protein Kinase 3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mitogen-Activated Protein Kinase 3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mitogen-Activated Protein Kinase 3", "description": "Comment diagnostiquer une dysfonction de MAPK3 ?\nQuels tests sont utilisés pour évaluer MAPK3 ?\nY a-t-il des biomarqueurs associés à MAPK3 ?\nMAPK3 est-elle impliquée dans des maladies spécifiques ?\nQuels symptômes peuvent indiquer un problème avec MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Visual+Fields&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mitogen-Activated Protein Kinase 3", "description": "Quels symptômes sont liés à une activation excessive de MAPK3 ?\nMAPK3 affecte-t-elle le système immunitaire ?\nQuels signes cliniques sont associés à MAPK3 ?\nY a-t-il des symptômes neurologiques liés à MAPK3 ?\nComment la MAPK3 influence-t-elle le stress cellulaire ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Visual+Fields&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mitogen-Activated Protein Kinase 3", "description": "Comment prévenir les dysfonctionnements de MAPK3 ?\nY a-t-il des habitudes à éviter pour MAPK3 ?\nLe stress peut-il affecter MAPK3 ?\nDes exercices spécifiques aident-ils MAPK3 ?\nLa gestion du poids influence-t-elle MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Visual+Fields&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mitogen-Activated Protein Kinase 3", "description": "Quels traitements ciblent MAPK3 ?\nLa thérapie génique peut-elle corriger MAPK3 ?\nQuels médicaments affectent la voie MAPK3 ?\nY a-t-il des traitements naturels pour MAPK3 ?\nComment la nutrition influence-t-elle MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Visual+Fields&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mitogen-Activated Protein Kinase 3", "description": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?\nMAPK3 est-elle liée à des maladies auto-immunes ?\nComment MAPK3 affecte-t-elle le cancer ?\nY a-t-il des risques cardiovasculaires liés à MAPK3 ?\nMAPK3 peut-elle influencer le vieillissement ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Visual+Fields&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mitogen-Activated Protein Kinase 3", "description": "Quels facteurs de risque sont associés à MAPK3 ?\nL'âge influence-t-il l'activité de MAPK3 ?\nY a-t-il des prédispositions génétiques pour MAPK3 ?\nLe mode de vie influence-t-il MAPK3 ?\nDes infections peuvent-elles affecter MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Visual+Fields&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction de MAPK3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer MAPK3 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de phosphorylation et les analyses protéomiques sont courants." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés à MAPK3 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de certaines protéines peuvent indiquer une dysfonction de MAPK3." } }, { "@type": "Question", "name": "MAPK3 est-elle impliquée dans des maladies spécifiques ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est liée à des cancers et des maladies inflammatoires." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec MAPK3 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes variés selon la maladie, comme la fatigue ou des douleurs chroniques." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une activation excessive de MAPK3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une activation excessive peut entraîner une inflammation et des douleurs." } }, { "@type": "Question", "name": "MAPK3 affecte-t-elle le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle joue un rôle dans la régulation de la réponse immunitaire." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à MAPK3 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des éruptions cutanées ou des troubles métaboliques peuvent apparaître." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques liés à MAPK3 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques peuvent survenir en cas de dysfonction de MAPK3." } }, { "@type": "Question", "name": "Comment la MAPK3 influence-t-elle le stress cellulaire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elle régule les réponses au stress, affectant la survie cellulaire et l'apoptose." } }, { "@type": "Question", "name": "Comment prévenir les dysfonctionnements de MAPK3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une bonne nutrition et de l'exercice, est recommandé." } }, { "@type": "Question", "name": "Y a-t-il des habitudes à éviter pour MAPK3 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le tabagisme et une alimentation riche en graisses saturées est conseillé." } }, { "@type": "Question", "name": "Le stress peut-il affecter MAPK3 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber la signalisation de MAPK3." } }, { "@type": "Question", "name": "Des exercices spécifiques aident-ils MAPK3 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des exercices réguliers peuvent améliorer la régulation de MAPK3." } }, { "@type": "Question", "name": "La gestion du poids influence-t-elle MAPK3 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un poids santé peut aider à réguler l'activité de MAPK3." } }, { "@type": "Question", "name": "Quels traitements ciblent MAPK3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques de MAPK3 sont en développement pour traiter certains cancers." } }, { "@type": "Question", "name": "La thérapie génique peut-elle corriger MAPK3 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est une approche potentielle pour corriger des mutations de MAPK3." } }, { "@type": "Question", "name": "Quels médicaments affectent la voie MAPK3 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les inhibiteurs de MEK peuvent moduler l'activité de MAPK3." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour MAPK3 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certaines plantes médicinales peuvent influencer la signalisation de MAPK3." } }, { "@type": "Question", "name": "Comment la nutrition influence-t-elle MAPK3 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants peut moduler l'activité de MAPK3." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme le cancer, l'inflammation chronique et des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "MAPK3 est-elle liée à des maladies auto-immunes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies dans MAPK3 peuvent contribuer à des maladies auto-immunes." } }, { "@type": "Question", "name": "Comment MAPK3 affecte-t-elle le cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une activation aberrante de MAPK3 est souvent observée dans divers types de cancer." } }, { "@type": "Question", "name": "Y a-t-il des risques cardiovasculaires liés à MAPK3 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre MAPK3 et des maladies cardiovasculaires." } }, { "@type": "Question", "name": "MAPK3 peut-elle influencer le vieillissement ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des dysfonctionnements de MAPK3 sont associés à des processus de vieillissement prématuré." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés à MAPK3 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'obésité, le tabagisme et le stress sont des risques connus." } }, { "@type": "Question", "name": "L'âge influence-t-il l'activité de MAPK3 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'activité de MAPK3 peut diminuer avec l'âge, affectant la signalisation cellulaire." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques pour MAPK3 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mutations génétiques peuvent prédisposer à des dysfonctionnements de MAPK3." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il MAPK3 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques." } }, { "@type": "Question", "name": "Des infections peuvent-elles affecter MAPK3 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales peuvent perturber la signalisation de MAPK3." } } ] } ] }

Sources (10000 au total)

Humphrey visual field made easy for residents.

Visual field testing is an indispensable part of the assessment of glaucoma. Of paramount importance to both the practitioner and the perimetrist is the guidance on how to conduct the test to get the ... To simplify the basics of understanding single-field analysis of visual field tests by using the Humphrey perimeter.... The general principle and a brief overview of how the Humphrey visual field is conducted and the approach to interpreting the results of single field analysis in an easy-to-understand manner are prese... This educational video is an attempt to simplify the interpretation of Humphrey visual field single-field analysis with illustrations and video clips that would be useful to practicing ophthalmologist... https://youtu.be/x8iZLDR4XdY....

Foveal avascular zone vessel density is associated with visual field progression in early-stage glaucoma eyes with central visual field damage.

We investigated the relationship between foveal avascular zone (FAZ)-related parameters, assessed by optical coherence tomography angiography (OCT-A), and visual field (VF) progression in early-stage ...

Visual feedback in the lower visual field affects postural control during static standing.

The dorsal parietal visual system plays an important role in self-motion perception and spatial cognition. It also strongly responds to visual inputs from the lower visual field. Postural control is m... Do visual stimuli presented to the lower and upper visual fields affect postural control and sensory reweighting?... Twenty-nine healthy young adults participated in the study. Four conditions (full visual field, upper visual field, lower visual field, and no optic flow condition) were simulated in a VR environment ... Optic flow in the full and lower visual fields produced significantly smaller 95 % ellipse area and RMS of COP in the anterior-posterior direction compared to optic flow in the upper visual field. Furth... Visual feedback affects static postural control more when presented in the lower visual field compared to the upper visual field....

Five-Year Visual Field Outcomes of the HORIZON Trial.

To compare visual field (VF) progression between glaucoma patients receiving cataract surgery alone (CS) or with a Hydrus microstent (CS-HMS).... Post hoc analysis of VF data from the HORIZON multicenter randomized controlled trial.... A total of 556 patients with glaucoma and cataract were randomized 2:1 to either CS-HMS (369) or CS (187) and followed up for 5 years. VF was performed at 6 months and then every year after surgery. W... Data from 352 eyes in the CS-HMS arm and 165 in the CS arm were analyzed (2966 VFs). The mean RoP was -0.26 dB/y (95% credible interval -0.36, -0.16) for CS-HMS and -0.49 dB/y (95% credible interval -... CS-HMS has a significant effect on VF preservation in glaucoma patients compared with CS alone, reducing the proportion of fast progressors....

Effect of trabeculectomy on the rate of progression of visual field damage.

This study quantifies the effect of trabeculectomy on the rate of progression (RoP) of visual field (VF) damage utilising pre- and post-operative visual function as the outcome instead of surrogate ou... Clinical and VF data from 199 sequential patients who underwent trabeculectomy between 2015 and 2016 were extracted from the network of sites of Moorfields Eye Hospital NHS Foundation Trust. Of these,... We analysed 10 [9,12] VFs per subject (Median [Interquartile Range]). At surgery, the age was 67 [57, 72] years, mean deviation was -10.84 [-14.7, -5.6] dB and the IOP was 18 [15, 20] mmHg. One year a... Trabeculectomy leads to a significant reduction in the RoP of VF loss postoperatively....

A Consensus Statement on the Terminology for Automated Visual Field Abnormalities.

A multitude of terms have been used to describe automated visual field abnormalities. To date, there is no universally accepted system of definitions or guidelines. Variability among clinicians create... In phase one of the study, all neuro-ophthalmologists in Israel were asked to complete a survey in which they described the abnormalities in 10 selected automated visual field tests. In phase 2 of the... Twenty-six neuro-ophthalmologists participated in the initial survey. On average, there were 7.5 unique descriptions for each of the visual fields (SD 3.17), a description of only the location in 24.6... The study confirmed a great degree of variability in the use of terminology to describe automated visual field abnormalities. The creation of a consensus statement was associated with improved use of ...

Gaze tracker parameters have little association with visual field metrics of intrasession frontloaded SITA-Faster 24-2 visual field results.

To determine the usefulness of Humphrey Field Analyser (HFA) SITA-Faster 24-2 gaze tracker outputs on interpreting intra-visit visual field (VF) result pairs.... Analysis of 1380 right-left eye pairs and 1432 pairs of test 1-test 2 intrasession VF results of patients seen within a university-based glaucoma service was undertaken to understand gaze deviation di... There was no association of test order (right-left, test 1-test 2) with eye movements. There was a significant, but weak correlation between eye movements and age (r = 0.16). Correlations of eye movem... Eye movement parameters as currently reported by the HFA do not appear to be correlated with key sensitivity parameters when considering the repeatability of intrasession SITA-Faster 24-2 VF results. ...

Peripheral visual field loss and activities of daily living.

Peripheral visual field (VF) loss affects 13% of the population over 65. Its effect on activities of daily living and higher order visual processing is as important as it is inadequately understood. T... In this review, glaucoma and retrochiasmal cortical damage are utilized as examples of peripheral field loss which typically spare central vision and have patterns respecting the horizontal and vertic... Peripheral VF loss is an under-recognized cause of patient distress and disability. All peripheral field loss is not the same, differential patterns of loss affect parameters of activities of daily li...